Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia TO THE EDITOR Double minutes (dmins) and homogeneously staining regions (hsrs) are found in a wide range of tumors and are generally associated with gene amplification, 1 disease progression, drug resistance, and often a poor prognosis.
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Even though reports of dmins are rare in leukemia, a number of studies have shown that the frequency varies, from less than 1% to 12.5%. 3, 4 However, with the advent of banding techniques, fewer cases with dmins have been reported. This is likely due to the trypsin treatment used in G-banding. Dmins have been described mostly in elderly patients with leukemias. To date, only one case of childhood leukemia (secondary T cell ALL) with dmins and other chromosomal abnormalities has been reported. 5 Most of the dmins described in leukemia are the result of amplification of the c-MYC gene. 6 We report the first case of a secondary myelodysplastic syndrome (MDS) with dmins and c-MYC amplification in a child after chemotherapy for acute lymphoblastic leukemia (ALL).
An 11-year-old girl was initially seen because of bruising and facial paralysis on the right side. Laboratory work-up revealed 11% blasts in the peripheral blood. A bone marrow aspirate demonstrated complete replacement by malignant lymphoblasts. Immunophenotyping by flow cytometry was consistent with a diagnosis of pre-B ALL; no coexpression of myeloid markers was observed. The DNA Index was 0.77 and 1.46 corresponding to the hypodiploid and hyperdiploid lines observed by cytogenetics. The patient was enrolled in the high-risk arm of the leukemia protocol at our institution. Because of leukemic CNS involvement at diagnosis, the patient also received radiation therapy to the base of skull (total dose, 12 Gy). The patient received induction chemotherapy with vincristine, prednisone, daunamycin, L-asparaginase, high-dose 6-mercaptopurine, and intrathecal methotrexate, hydrocortisone and cytarabine. Therapy was complicated by severe avascular necrosis of both femoral heads and herpes simplex keratitis. She had full resolution of her neurologic deficit and maintained complete continuous remission until the time of relapse.
The patient remained well until 4.5 years after the initial diagnosis, at which time she presented with symptoms of fatigue and easy bruising. Examination of peripheral blood revealed thrombocytopenia (platelet count, 52 × 10 9 /l) and a normal white blood cell count (6.1 × 10 9 /l), with a differential leukocyte count of 46% lymphocytes, 3% monocytes, 4% blasts, 10% promyelocytes, 2% metamyelocytes, 3% myelocytes, 4% bands, and 28% neutrophils. Rare Auer rods were also noted. Mature neutrophils demonstrated some dysplastic features, including hypogranulation and pseudo-Pelger-Huet changes.
Analysis of a bone marrow aspirate revealed hypercellularity, with a markedly increased myeloid:erythroid ratio and a predominance of promyelocytes (69% of nucleated cells, Figure 1 ). The promyelocytes contained immature chromatin, and many were nucleolated. Myeloblasts comprised 2.5% of the cells and rarely contained Auer rods. Neither the morphologic features nor the cytogenetic changes (see below) were compatible with a diagnosis of acute promyelocytic leukemia. These findings suggested a high-grade MDS, classified as refractory anemia with excess blasts (RAEB) in transformation by FAB criteria. Subsequent analyses of bone marrow aspirates showed essentially identical findings.
The patient was given supportive care for the next 9 weeks, at which time her white blood cell count had risen to 10 × 10 9 /l with 1% blasts, 23% promyelocytes, 10% myelocytes, and 6% metamyelocytes. She was enrolled in the AML '97 protocol at our institution. She 
Figure 1
Bone marrow examination at the time of conversion from ALL to MDS. The aspirate smear reveals little myeloid maturation beyond the promyelocyte stage (May-Grü nwald Giemsa stain; 1000 × original magnification). A minor population of blasts was present, rarely containing Auer rods (not shown).
received Ara-C 500 mg/m 2 days 1-5 and 2-chloro-deoxyadenosine, 9 mg/m 2 days 2-6. Her clinical course was complicated by delayed marrow recovery, sinusitis, and Candida tropicalis sepsis. She developed multisystem organ failure and died 1 month later after initiating AML therapy. Post-mortem examination, limited to the chest and abdomen, revealed disseminated candidiasis involving the lungs, heart, liver, kidneys, and spleen.
When the patient was initially diagnosed with ALL, cytogenetic analysis showed: 37,XX,−2,−3,−4,−7,−9,−12,−15,−16,−20 [5] /68,XX, +X,+X,+1,+1,+5,+6,+?7,+8,+10,+11,+13,+15,+17,+18,+19,+19,+20,+21, +21,+22,+22,+22 [1] /46,XX [2] (data not shown). These two related lines correlated with the observed DNA index of 0.77 and 1.46. Thus, the patient had hypodiploidy/hypotriploidy DNA content that is associated with a poor prognosis. At the time of conversion to MDS, the karyotype showed: 44,XX,−5,−9,t(6;16)(q23;q13),add(17)(p11.2) [9] / 46,XX [5] (data not shown). Dmins in the range of 7 to Ͼ100 per metaphase were observed (Figure 2a) . The diagnostic sample of ALL was reevaluated for dmins, and no dmins were observed (data not shown). Fluorescence in situ hybridization with the c-MYC probe (Ventanta/Oncor, Tucson, AZ, USA) showed that the dmins resulted from the amplification of the c-MYC gene, which is located on 8q24. The number of dmins varied from cell to cell (Figure 2b) . Dmin chromosomes have been described in both de novo and therapy-related AML and MDS. 6, 7 However, amplified DNA sequences in acute leukemia have not been well characterized by molecular methods. Of the cases identified with dmins, molecular studies showed that the c-MYC gene is amplified in most cases. 6 Dmins tend to occur in elderly patients who had AML or MDS. 6, 7 To date, dmins have been observed in only one case of childhood secondary T cell ALL. 5 In most reported cases, dmins have occurred in association with other complex chromosomal abnormalities, or chromosomal aneusomy. Dmins have also been observed in a patient with a normal karyotype. 8 Also, an association of dmins with trisomy 4 has been described. 6 In the present study, a combination of conventional cytogenetics and molecular studies identified c-MYC amplification in a child with secondary MDS and dmins. At the time of conversion to MDS, the patient had hypodiploid chromosomes with monosomy of chromosomes 5 and 9, t(6;16), add(17p), and dmins. Monosomy 5 is frequently observed in adult cases of therapy-related MDS. 9 Loss or rearrangement of the short arm of chromosome 17 has also been described in cases with dmins. Potentially, loss or mutation of p53 alleles can amplify endogenous genes via perturbations in cell cycle regulation in vitro. 10 The reported frequency of dmins in acute leukemias varies considerably. This may reflect the varying sensitivity of different cytogenetic techniques in detecting dmins. It is evident that frequency of cases with dmins was higher in the prebanding era; whereas, since the introduction of G-banding as the standard technique for cytogenetic analysis, fewer cases have been reported. The disparity in the frequencies with which dmins are observed using these two techniques Leukemia is due to the loss of dmins during trypsinization employed in the Gbanding procedure. However, Giemsa staining without trypsinization will enhance the identification of dmin. Dmins are thought to be different from acentric fragments and are not lost in cell division. Therefore, it is possible that this important prognostic cytogenetic marker is not being identified in routine cytogenetic analyses and that cytogeneticists may be overlooking dmins, especially in cases of secondary malignancies.
Most of the reported cases of MDS with dmins are associated with RAEB and have had an aggressive clinical course with typical survival of less than 3 months. 7 Likewise, c-MYC amplification also portends a poor prognosis. 6 Our patient with secondary MDS had an aggressive clinical course consistent with that of other cases with dmins, although her fulminant deterioration was likely to be multifactorial in nature. In conclusion, this case illustrates the need for the careful diagnostic evaluation with appropriate techniques as well as attention to clinical features of presentation to understand the underlying genetic mechanism leading to the poor response of patients with dmins and c-MYC amplification.
